问题 › 小型企业咨询服务 › HealthTech与数字健康
数字健康运营商的咨询市场缺乏监管，质量参差不齐，因此选对顾问才是关键，而常见的推荐方式只看个人契合度，不看阅读风险份额和参与率的能力。 数字健康公司面临特定困境——结果风险承诺的速度快于公司判断自身能否承担的速度，12个月测量窗口对11个月销售周期。除非定价，否则风险收入份额将继续无从归因地变动，产品或岗位贡献的争论也将停留在意见层面。
数字健康运营商的咨询市场缺乏监管，质量参差不齐，因此选对顾问才是关键，而常见的推荐方式只看个人契合度，不看阅读风险份额和参与率的能力。 数字健康公司面临特定困境——结果风险承诺的速度快于公司判断自身能否承担的速度，12个月测量窗口对11个月销售周期。除非定价，否则风险收入份额将继续无从归因地变动，产品或岗位贡献的争论也将停留在意见层面。
结构性问题是运营商必须在观察自身参与率和归因结果能否支撑已签份额前就承诺结果风险，而没有标准资质能显示顾问是否正确诊断了这一缺口。
其次值得注意的是，决定性变量存在于现有数据中：风险份额在应用毛利率和PMPM后是否覆盖，标识流失是由交付能力还是需求驱动，以及测量窗口是否比销售周期更快收紧。
需注意的失效模式是对每家运营商都采用固定行动序列，通常是提高风险份额、增加结果跟踪和收紧参与目标的组合，当约束实际是标识流失或利润压缩时，每一项都会产生相反结果。
诊断审查先处理运营商自身的风险份额、参与率和标识流失，显示哪个杠杆被卡住，然后再考虑更大承诺，包括数据表明进一步分析不会改变现场产能需求的情况。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 提案在检查运营商的风险份额或当前参与率前就列出固定干预序列。
✓ 顾问在审查测量窗口和标识流失数据前就提出PMPM或结果归因的建议变更。
✓ 顾问无法指出此前客户中参与率低于预期且风险份额必须重新谈判的案例。
通常会让情况更糟的做法。 按融洽度和推荐选择，这是判断会议是否有用而非判断建议是否匹配运营商自身风险份额和标识流失所见约束的好坏过滤器。
It is for you if you run or finance a digital health company and the proposal describes a programme rather than a diagnosis. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长策略, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
对于一项明确工作——定价审查、盈利能力分析、增长诊断——£3k–£15k是正常中端市场区间，通常已足够。开放式月度 retainer £1,500–£5,000常见，仅在有持续交付而非持续建议时才值得。如果每月支付会议费用，会议应产出可命名的决策。
更多时候是后者，而市场承认得不够。小型企业战略问题的很大一部分，可通过拆分企业已生成但仅总体查看的数字来回答。如果从未有人向您展示按产品、客户和渠道的贡献，该分析就是第一笔购买，且费用不高。
教练针对所有者；顾问针对业务。教练处理您回避的决策、习惯和问责，确实对部分所有者有帮助。顾问处理正确决策是什么。混淆两者常见，为问责支付咨询费用是代价更高的错误方向。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית